drugset
Drugs / High-Dose Influenza Vaccine
last change Oct 2025 re-read 3 minutes ago

High-Dose Influenza Vaccine

also known as QIV-HD

Vaccine

Developed for
influenza
Investigated by
Saad Jamshed MD · Sanofi · Sanofi Pasteur, a Sanofi Company

Trials 2

today NCT04024228 · Ph 3 NCT01666782 · Ph 2
201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT01666782 Aug 2012 → Jun 2015 cancer, influenza Saad Jamshed MD Completed No outcome recorded
Phase 31 trial · 1 met primary
Phase 3 NCT04024228 Oct 2019 → Jan 2020 — Sanofi Pasteur, a Sanofi Company Completed Met primary

Press releases naming this drug 3 releases

DateIssuerRelease
2025-10-20 Sanofi Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose sanofi.com ↗
2021-10-07 Sanofi Sanofi: Positive results from the first study of high-dose influenza vaccine with a COVID-19 mRNA booster support co-administration recommendations sanofi.com ↗
2021-03-31 Sanofi Sanofi to build new facility in Canada to increase global availability of high-dose influenza vaccine sanofi.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as High-Dose Influenza Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT04024228 ↗
1

NCT01666782 ↗
Known as QIV-HD “High-Dose Influenza Vaccine (split virion, inactivated), Quadrivalent (QIV-HD) 2019-2020 Northern Hemisphere formulation” NCT04024228 ↗
Modality Vaccine “high-dose influenza vaccine” NCT01666782 ↗
Route Intramuscular “Route of administration: IM” NCT04024228 ↗